Question 4 - SIU Kidney Cancer Quiz

Level: Difficult

QUESTION 1:
Which of the following drugs is a HIF-2α inhibitor?

a) Savolitinib b) Lenvatinib c) Avelumab d) Sunitinib e) Belzutifan

Correct

Incorrect, the correct answer is e

Submit

Level: Difficult

QUESTION 2:
The triplet combination of cabozantinib/nivolumab/ipilimumab is statistically significant superior to ipilimumab/nivolumab with regards to:

a) Progression-free survival and response rate b) None of these options c) Overall survival and response rate d) Response rate and duration of response e) Progression-free survival

Correct

Incorrect, the correct answer is e

Submit

Level: Difficult

QUESTION 3:
Which treatment regimen provides an overall survival benefit for the following patient:

62-year-old male, nephrectomy January 2022, lung and lymph node metastases March 2023, ECOG performance of 1, and neutrophils 5.9 (normal range 2.0-8.0), hemoglobin 137 (normal range 135-170), platelets 307 (normal range 150-400), sodium 132 (normal range 135-145), creatinine 125 (normal range 60-115), calcium 2.41 (normal range 2.18-2.58), albumin 37 (normal range 35-45), LDH 510 (normal range 90-225).

a) Nivolumab/ipilimumab b) Pembrolizumab/axitinib + Pembrolizumab/lenvatinib c) None of these options d) Pembrolizumab/lenvatinib e) Pembrolizumab/axitinib

Correct

Incorrect, the correct answer is c

Submit

Level: Difficult

QUESTION 4:
How many patients in the cabozantinib/nivolumab/ipilimumab arm of COSMIC-313 discontinued any component of their treatment regimen and how many required high-dose steroids (≥40 mg prednisone or prednisone equivalent for any duration) at some point in their treatment?

a) 29% and 34% b) 45% and 58% c) 67% and 30% d) 20% and 5% e) 31% and 78%

Correct

Incorrect, the correct answer is b

Submit

Level: Difficult

QUESTION 5:
Which of the following RCC subtypes may be caused by fumarate hydratase mutations?

a) Collecting duct carcinoma b) Chromophobe c) Renal medullary RCC d) Papillary type 2 e) Papillary type 1

Correct

Incorrect, the correct answer is d

Submit

All ready? OK, come on in, Doctor!

Continue

Level: Difficult

QUESTION 1:Which of the following drugs is a HIF-2α inhibitor?

Level: Difficult

QUESTION 2:The triplet combination of cabozantinib/nivolumab/ipilimumab is statistically significant superior to ipilimumab/nivolumab with regards to:

Level: Difficult

Level: Difficult

QUESTION 4:How many patients in the cabozantinib/nivolumab/ipilimumab arm of COSMIC-313 discontinued any component of their treatment regimen and how many required high-dose steroids (≥40 mg prednisone or prednisone equivalent for any duration) at some point in their treatment?

Level: Difficult

QUESTION 5:Which of the following RCC subtypes may be caused by fumarate hydratase mutations?

QUESTION 1:
Which of the following drugs is a HIF-2α inhibitor?

QUESTION 2:
The triplet combination of cabozantinib/nivolumab/ipilimumab is statistically significant superior to ipilimumab/nivolumab with regards to:

QUESTION 4:
How many patients in the cabozantinib/nivolumab/ipilimumab arm of COSMIC-313 discontinued any component of their treatment regimen and how many required high-dose steroids (≥40 mg prednisone or prednisone equivalent for any duration) at some point in their treatment?

QUESTION 5:
Which of the following RCC subtypes may be caused by fumarate hydratase mutations?